peptide therapy for fat loss
Peptide therapy for fat loss refers to the use of specific peptides and peptide-like compounds that are being studied for their potential to influence appetite, metabolism, fat storage, body composition, energy, and recovery. Peptides are short chains of amino acids that act as tiny messengers in the body, helping to coordinate signals between cells, hormones and organ systems.
Category 1: Adipose-Targeting & Fat-Metabolism Peptides
5-Amino-1MQ
What it is: 5-Amino-1MQ is a small, peptide-like compound studied for its ability to inhibit an enzyme called nicotinamide N-methyltransferase (NNMT) in fat cells. NNMT activity is linked with how adipocytes handle energy and store fat.
How it works: By reducing NNMT activity, 5-Amino-1MQ may help shift cellular pathways toward increased energy expenditure and changes in NAD+-related signalling in adipose tissue.
Potential benefits: May influence body weight, fat mass and cardiometabolic markers in diet-induced obesity models.
Typical use cases/goals: 5-Amino-1MQ is examined in the context of obesity, metabolic dysfunction, insulin resistance, and cardiometabolic health.
Adipotide
What it is: Adipotide is a synthetic compound designed to target blood vessels that supply white adipose (fat) tissue. It is sometimes referred to as a “vasculature-targeting” weight-loss research compound.
How it works: Adipotide binds to specific markers on the surface of blood vessels in white fat and delivers a signal that can trigger programmed cell death in those vessels.
Potential benefits: Supports reductions in body weight, improved insulin sensitivity and shifts in fat distribution.
Typical use cases/goals: Adipotide has been studied mainly in laboratory and early-phase clinical settings for obesity and metabolic syndrome, and also as a model for targeted vascular therapies.
AOD-9604 (GH Fragment 176-191)
What it is: AOD-9604 is a laboratory-synthesized fragment of human growth hormone (amino acids 176-191) designed to focus on fat metabolism rather than the full spectrum of GH effects.
How it works: This fragment appears to increase fat breakdown (lipolysis) and reduce the formation of new fat (lipogenesis), particularly in adipose tissue, while having less impact on growth, insulin or blood sugar than the whole growth hormone.
Potential benefits: Can influence body fat, body weight and lipid metabolism, especially in diet-induced obesity models.
Typical use cases/goals: AOD-9604 is primarily discussed in the context of obesity and fat metabolism, and secondarily, joint or cartilage effects.
Category 2: Appetite & Gut–Brain Signalling Peptides
Cagrilintide
What it is: Cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin that helps regulate satiety and meal size. It is being developed specifically for chronic weight-management indications.
How it works: By activating amylin receptors in the brain, cagrilintide can enhance feelings of fullness, slow gastric emptying, and reduce overall energy intake. It works along the gut–brain axis, complementing other appetite-related hormones.
Potential benefits: May reduce body weight and waist circumference when used alone and in combination with GLP-1 receptor agonists. Participants often experience smaller portions and decreased snacking.
Typical use case/goals: Cagrilintide is often evaluated alongside nutrition and lifestyle counselling.
Semaglutide
What it is: Semaglutide is a GLP-1 receptor agonist originally developed to support blood sugar control in type 2 diabetes and now approved in many regions for chronic weight management at higher doses.
How it works: Semaglutide mimics the effect of the natural hormone GLP-1, enhancing insulin release when glucose is high, reducing glucagon, slowing stomach emptying and acting on appetite centers in the brain. Together, these actions can reduce hunger, increase satiety and lower daily calorie intake.
Potential benefits: Semaglutide, when combined with nutrition and lifestyle support, can lead to substantial average weight reduction and improvements in several cardiometabolic markers such as blood pressure, cholesterol and blood sugar control.
Typical use cases/goals: Semaglutide is studied for chronic weight management, type 2 diabetes, and broader cardiometabolic risk reduction.
Tirzepatide
What it is: Tirzepatide is a dual GIP and GLP-1 receptor agonist approved in several countries for type 2 diabetes and chronic weight management. It acts on two incretin pathways simultaneously.
How it works: By activating both GIP and GLP-1 receptors, tirzepatide amplifies insulin secretion when blood sugar is elevated, reduces glucagon levels, slows gastric emptying and influences appetite regulation in the brain. This combined effect can reduce energy intake and improve glucose control.
Potential benefits: May see large average reductions in body weight and waist circumference, along with improved glycemic control and changes in markers such as triglycerides and blood pressure.
Typical use cases/goals: Tirzepatide is evaluated for people with obesity (with or without diabetes), metabolic syndrome, and related conditions such as fatty liver disease, usually within structured lifestyle programs.
Retatrutide
What it is: Retatrutide is a “triple agonist” that activates GIP, GLP-1 and glucagon receptors at the same time. It is being studied as a next-generation metabolic therapy.
How it works: The GLP-1 and GIP actions primarily target appetite and glucose balance, while the glucagon component may increase energy expenditure and fat oxidation. Together, this tri-hormone approach aims to complement appetite reduction by altering how the body burns calories.
Potential benefits: Can produce very significant average weight reductions and improvements in liver fat and cardiometabolic risk markers.
Typical use cases/goals: Retatrutide is studied in adults with obesity, with and without type 2 diabetes, and in participants with metabolic fatty liver disease.
Tesofensine
What it is: Tesofensine is technically a small molecule rather than a peptide, studied for its potential metabolic function. It works as a triple monoamine reuptake inhibitor, affecting norepinephrine, dopamine and serotonin.
How it works: By increasing levels of these neurotransmitters in the brain, tesofensine can reduce appetite and may modestly raise energy expenditure. It primarily acts on hypothalamic centers that control hunger and satiety.
Potential benefits: can observe notable average weight loss compared with placebo in people with obesity, along with changes in body composition and quality-of-life measures.
Typical use cases/goals: Tesofensine is studied in obesity trials and in combination formulations for specific metabolic conditions.
Category 3: GH / IGF-1 Axis Peptides & Body Composition
CJC-1295
What it is: CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) designed to have a longer half-life by binding to albumin in the bloodstream.
How it works: CJC-1295 stimulates the pituitary gland to release the body’s own growth hormone in pulses, which in turn can increase IGF-1 levels. Over time, this signalling may influence lean mass, fat distribution, and other aspects of body composition.
Potential benefits: May observe sustained increases in GH and IGF-1 after dosing, with potential downstream effects on lean mass and fat mass in specific populations.
Typical use cases/goals: Growth hormone deficiency, age-related changes in body composition and, in some circles, general wellness or performance.
Ipamorelin
What it is: Ipamorelin is a pentapeptide growth hormone secretagogue that activates the ghrelin (GHS) receptor. It is designed to stimulate GH release with relative selectivity.
How it works: By binding to GHS receptors in the pituitary and hypothalamus, ipamorelin encourages pulsatile GH release without strongly affecting other pituitary hormones. This can influence muscle, bone and connective tissue turnover.
Potential benefits: Can support lean mass and bone formation and counter some catabolic states.
Typical use cases goals: Growth disorders, steroid-induced catabolism, postoperative recovery and as part of combination protocols with GHRH analogues (such as CJC-1295).
Tesamorelin
What it is: Tesamorelin is a synthetic GHRH analogue which can help reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
How it works: By stimulating growth hormone release, tesamorelin increases IGF-1 and can preferentially reduce visceral adipose tissue (VAT) within the abdominal cavity.
Potential benefits: May support reductions in VAT and improvements in some lipid and metabolic parameters.
Typical use cases/goals: May have impacts on fatty liver disease and broader metabolic risk factors in selected patient groups.
Follistatin
What it is: Follistatin is a naturally occurring protein that binds and neutralizes myostatin and certain activins, which normally limit muscle growth. It is being explored in protein, peptide and gene-therapy forms.
How it works: By reducing myostatin signalling, follistatin can allow muscle tissue to grow more readily in animal models, often accompanied by reductions in body fat and changes in muscle fibre size.
Potential benefits: Research suggests that increasing follistatin activity may promote muscle hypertrophy, improve strength and alter body-fat distribution.
Typical use cases/goals: Follistatin is primarily studied for muscle-wasting diseases, age-related sarcopenia and certain orthopedic or performance-related applications. Its role in general weight management is indirect via changes in body composition.
Multi‑Nutrient “Wellness” IVs and the Stress Response
Multi-nutrient formulations (sometimes modelled after “Myers’ Cocktails”) typically combine Vitamin B, Vitamin C and magnesium with electrolytes. For stress-relief IV therapy, the goal is to address hydration and multiple nutrient routes simultaneously.
A blend of vitamins, minerals and other substances is infused into an IV. Exact doses and ingredients used may vary, and are also adjusted according to individual health goals and screenings.
What is the mechanism?
- A combination of vitamin cofactors to support antioxidant defences and neuromuscular functions, as well as metabolic enzymes.
- Fluids and electrolytes help maintain hydration, which in turn may reduce headaches, fatigue and improve overall well-being.
- This type of IV aims to create an environment that is conducive to recovery from daily stressors.
Potential benefits
- Can influence symptoms like fatigue, “wired-but-tired” states or mild tension if nutrient deficiencies and dehydration contribute to the cause.
- After therapy, some people experience a subjective sense of calmness, reduced muscle tension or an improved ability to manage busy schedules.
Typical Uses
- People who have multiple concerns, such as lack of sleep, a busy schedule, high stress and poor nutrition.
- Support for recovery during or after high-demand periods such as travel, major life events or sustained workplace stress.
Category 4: Mitochondrial & Cellular-Energy Modulators
MOTS-C
What it is: MOTS-C is a 16-amino-acid peptide encoded within mitochondrial DNA, described as a “mitochondrial-derived peptide.” It has attracted interest for its potential roles in metabolism and aging.
How it works: MOTS-C appears to target skeletal muscle and other tissues, influencing AMPK and related pathways that govern glucose uptake and fat utilization. It can improve the way cells respond to metabolic stress.
Potential benefits: Studies suggest that MOTS-C may reduce diet-induced obesity, improve insulin sensitivity and enhance exercise capacity.
Typical use cases/goals: Researchers are exploring MOTS-C for obesity, type 2 diabetes, exercise performance and healthy aging, generally in preclinical or early-phase settings.
SLU-PP-332
What it is: SLU-PP-332 is a synthetic small molecule often described as an “exercise mimetic.” It is not a peptide but acts similarly due to its metabolic focus.
How it works: SLU-PP-332 activates estrogen-related receptors (ERRs), which regulate genes involved in mitochondrial function and oxidative metabolism.
Potential benefits: In preclinical studies, SLU-PP-332 has been associated with reductions in body weight and fat mass, improved glucose tolerance and better metabolic profiles in animals with diet-induced metabolic syndrome.
Typical use cases/goals: Research focuses on metabolic syndrome, obesity and age-related declines in mitochondrial function.
NAD+ (and NAD+-focused therapies)
What it is: NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every cell, central to energy production and DNA repair. “NAD+ therapy” commonly refers to IV infusions or oral precursors such as nicotinamide riboside or nicotinamide mononucleotide.
How it works: Increasing NAD+ availability can support mitochondrial energy production, sirtuin activity and cellular stress responses.
Potential benefits (under research): Studies of NAD+ precursors have shown increases in NAD+ levels and modest changes in some cardiometabolic markers.
Typical use cases/goals: NAD+-related therapies are being studied for metabolic syndrome, neurodegenerative conditions, exercise performance and general “healthy aging,” as supportive or adjunctive interventions.
SS-31 (Elamipretide)
What it is: SS-31, or elamipretide, is a small synthetic peptide that selectively targets mitochondria by binding to cardiolipin in the inner mitochondrial membrane.
How it works: By stabilizing mitochondrial structure and reducing oxidative stress, SS-31 aims to improve ATP production and overall cellular energy efficiency. In several disease models, it supports tissues that are highly energy-dependent, such as the heart and skeletal muscles.
Potential benefits: Clinical and preclinical studies have evaluated SS-31 for heart failure, mitochondrial myopathies, kidney disease and certain rare genetic conditions.
Typical use cases/goals: The main focus is on rare mitochondrial diseases and organ-specific dysfunction. Any impact on weight or body composition would be secondary to improved energy handling and physical functioning.
Category 5: Supportive & Combination Peptides
Some peptides are not primarily “fat-loss” agents but may support aspects of health that indirectly relate to body composition:
- Recovery & tissue support (BPC-157, TB-500, PEG-MGF, KPV, LL-37 and combinations): These are being studied for wound healing, tendon and ligament support, joint comfort, inflammation and immune modulation. By helping people move more comfortably or recover from injury, they may support a more active lifestyle.
- Gut-focused variants (oral BPC-157, oral KPV, oral LL-37): These combinations are explored for gut lining support, microbiome balance and inflammatory bowel conditions, which may influence nutrient absorption and overall well-being.
- Neurocognitive & sleep peptides (DSIP, Semax, Selank, and blends): These agents are researched for their potential roles in stress response, mood regulation, focus and sleep quality. Better sleep and stress management can contribute to appetite regulation and healthier lifestyle choices.
- Longevity & aesthetic agents (Epithalon, FoxO4-DRI, GHK-Cu, and their combinations): These are primarily associated with cellular aging, skin quality, hair health, and connective tissue health. Any connection to weight is indirect, through overall vitality, rehabilitation or adherence to activity programs.
Endocrine & sexual-health peptides (Gonadorelin, Kisspeptin, Oxytocin, Melanotan-II, PT-141): These focus on reproductive hormone balance, libido and intimacy. Hormonal balance can affect energy, mood and motivation, which may contribute to lifestyle-driven changes in body composition.
Peptide | Category / Focus | Main mechanism described in research | Typical research goals* |
5-Amino-1MQ | Metabolism | Inhibits NNMT in adipocytes, altering NAD+-related pathways | Obesity, metabolic dysfunction, insulin resistance (preclinical) |
Adipotide | Adipose vasculature | Targets blood supply to white fat, leading to fat-tissue regression in models | Obesity and metabolic syndrome (preclinical and early human) |
AOD-9604 | GH fragment | GH-derived fragment studied for lipolysis and reduced fat formation | Obesity and fat-metabolism research, joint/cartilage effects |
Cagrilintide | Appetite / amylin | Long-acting amylin analogue enhancing satiety and slowing gastric emptying | Chronic weight-management trials, often in combination therapies |
Semaglutide | GLP-1 agonist | Mimics GLP-1 to reduce appetite, improve glucose control and slow gastric emptying | Chronic weight management, type 2 diabetes, cardiometabolic risk |
Tirzepatide | Dual GIP/GLP-1 agonist | Engages two incretin receptors to influence appetite and glucose balance | Obesity with/without diabetes, metabolic syndrome, fatty liver |
Retatrutide | Triple agonist | Activates GIP, GLP-1 and glucagon receptors to reduce intake and increase expenditure | Investigational obesity and metabolic liver disease therapy |
Tesofensine | Monoamine modulator | Inhibits NE/DA/5-HT reuptake to suppress appetite | Obesity trials, combination metabolic agents |
CJC-1295 | GH axis | Long-acting GHRH analogue increasing GH and IGF-1 | GH deficiency, age-related body-composition changes (research) |
Ipamorelin | GH secretagogue | Ghrelin receptor agonist promoting pulsatile GH release | Catabolic states, body composition and bone-health research |
Tesamorelin | GHRH analogue | Increases GH/IGF-1 to reduce visceral abdominal fat | HIV-associated lipodystrophy (approved), fatty liver research |
Follistatin | Myostatin binder | Neutralizes myostatin/activins to promote muscle growth | Muscle-wasting conditions, body-composition research |
MOTS-C | Mitochondrial peptide | Influences AMPK and metabolic stress pathways in muscle and other tissues | Obesity, insulin resistance, exercise capacity (mostly preclinical) |
SLU-PP-332 | Exercise mimetic | ERR agonist enhancing mitochondrial and oxidative metabolism | Metabolic syndrome, obesity, aging (preclinical) |
NAD+ | Coenzyme / energy | Supports cellular redox reactions and sirtuin-mediated stress responses | Healthy aging, metabolic and neurodegenerative conditions |
SS-31 (Elamipretide) | Mitochondrial peptide | Stabilizes mitochondrial membranes and reduces oxidative stress | Mitochondrial diseases, heart failure, fatigue-related conditions |
